Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals-Reference-Cited by-同舟云学术

Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals

Published:2013-02 Issue:2 Volume:40 Page:155-166
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Zimmermann Richard G.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Molecular Medicine

Reference34 articles.

1. Développement de radiopharmaceutiques et contraintes industrielles (Development of radiopharmaceuticals and industrial constraints);Zimmermann;Médecine Nucléaire - Imagerie Fonctionnelle et Métabolique,2005

2. Industrial constraints in the selection of radionuclides and the development of new radiopharmaceuticals;Zimmermann;World J Nucl Med,2008

3. Subjective perception of radiation risk;Freudenberg;J Nucl Med,2011

4. Nuclear medicine at a crossroad;Schelbert;J Nucl Med,2011

5. Research Strategy – Commentary: the promise of nuclear medicine;Zimmermann;Med Nous,2009

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lutetium-177 radioisotope and therapeutic radiopharmaceuticals: Production, separation and purification, chelation labeling and clinical application;Chinese Science Bulletin;2024-04-12

2. Immunological effects of radiopharmaceutical therapy;Frontiers in Nuclear Medicine;2024-04-04

3. Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000–2022);Journal of Medicinal Chemistry;2023-04-03

4. Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts;Cancer Nanotechnology;2023-02-27

5. Production of [11C]Carbon Labelled Flumazenil and L-Deprenyl Using the iMiDEV™ Automated Microfluidic Radiosynthesizer;Molecules;2022-12-13